Issues
-
Cover Image
Cover Image
Multiple studies have shown that engraftment and subsequent growth rates of human mammary tumor xenografts can be enhanced by coinjection of tumor cells with human fibroblasts or fibroblast-derived soluble factors. It is also apparent that the ability of a given mesenchymal fibroblast to enhance tumor growth is dependent on its tissue of origin (i.e., organ-specificity). However, it is unclear how organ-specific fibroblasts contribute to tumor growth enhancement and how these cells may impact organ-specific metastatic patterning. We examined a panel of primary human mesenchymal fibroblasts to define the extent to which each cell type could impact human breast cancer cell growth and invasion. Two- and three-dimentional in vitro systems in conjunction with in vivo animal models demonstrated that interleukin-6 (IL-6) was a critical factor that promoted human breast cancer cell growth and invasion via downstream STAT3 signaling events. In conjunction with clinical data that link elevated IL-6 to poor clinical outcomes in breast cancer patients, our data suggest that IL-6 may be a critical factor in human breast cancer disease progression. For details, see the article by Studebaker and colleagues on page 9087 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
AACR Centennial Series
Reviews
Priority Reports
Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice
Cell, Tumor, and Stem Cell Biology
Endocrinology
Epidemiology
Prevalence, Acquisition, and Clearance of Cervical Human Papillomavirus Infection among Women with Normal Cytology: Hawaii Human Papillomavirus Cohort Study
Routine Diagnostic X-ray Examinations and Increased Frequency of Chromosome Translocations among U.S. Radiologic Technologists
Association Study of Prostate Cancer Susceptibility Variants with Risks of Invasive Ovarian, Breast, and Colorectal Cancer
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells
Molecular Biology, Pathobiology, and Genetics
DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG Island Hypermethylation and Contributes to Metastatic Tumor Heterogeneity
Roles for MicroRNAs, miR-93 and miR-130b, and Tumor Protein 53–Induced Nuclear Protein 1 Tumor Suppressor in Cell Growth Dysregulation by Human T-Cell Lymphotrophic Virus 1
Common Familial Colorectal Cancer Linked to Chromosome 7q31: A Genome-Wide Analysis
Prevention
Systems Biology and Emerging Technologies
Tumor Microenvironment
The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma
Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA
Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6–Dependent Manner
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.